Spyre Therapeutics logo

Spyre Therapeutics

San Francisco, CA

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

spyre.com

Company Details

Founded

2023

Employees

87 employees

Raised

$1,100,999,936

Headquarters Location

San Francisco, CA

Public

Yes

Acquired

Yes

CEO

Cameron TurtleCameron Turtle

Founders

David G Lowe
David G Lowe

Company Collections

These are collections Spyre Therapeutics is a part of. Click on the collection name to view similar companies.

Spyre Therapeutics' Industries

Spyre Therapeutics' Tech Stack

Current Job Listings

Listing 0 of 2 job openings

    Spyre Therapeutics Headquarters Location

    San Francisco, CA 94115

    Total Amount Raised: $1,100,999,936

    Spyre Therapeutics Funding Rounds

    • Post Ipo Equity

      $275,000,000

    • Post Ipo Equity

      $200,000,000

    • Post Ipo Equity

      $180,000,000

      Post Ipo Equity Investors

      Perceptive Advisors
      Boxer Capital
      Deep Track Capital
      Adage Capital Management
      Farallon Capital Management
      Logos Capital
      Avidity Partners Management
      RTW Investments
      Darwin Global

    • Post Ipo Equity

      $180,000,000

      Post Ipo Equity Investors

      Affinity Asset Advisors
      Great Point Capital
      Boxer Capital
      Commodore Capital
      Deep Track Capital
      Woodline Partners
      Access Industries
      Cormorant Asset Management
      Venrock Healthcare Capital Partners
      RTW Investments
      Perceptive Advisors
      Fairmount Funds Management
      Braidwell
      Polar Capital Holdings

    • Post Ipo Equity

      $210,000,000

    • IPO

      Unknown

    • Series B

      $44,000,000

      Series B Investors

      Lilly Ventures
      Novartis Venture Fund
      New Ground Ventures
      UT Horizon Fund
      RA Capital Management
      Cowen Healthcare Investments
      Venrock
      OrbiMed Advisors
      Ally Bridge Group
      Jennison Associates
      Rock Springs Capital

    • Series A

      $12,000,000

      Series A Investors

      Lilly Ventures
      KBI Biopharma
      Novartis Venture Fund
      UT Horizon Fund
    Funding info provided by Diffbot.

    Spyre Therapeutics Reviews

    0 out of 5 stars

    Based on 0 reviews

    Review data

    Share your thoughts

    Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Spyre Therapeutics.

    Recent reviews